Anti-Covid drugs potent against Omicron, antibody therapies less effective: Study


PTI, Jan 28, 2022, 10:38 AM IST

Washington DC: The current drugs to treat COVID-19 remain very effective against the Omicron variant of the SARS-CoV-2 virus, according to a laboratory study.

However, available antibody therapies — typically given intravenously in hospitals — are substantially less effective against Omicron compared to earlier variants of the virus, the researchers said.

The lab tests also showed that some antibodies have entirely lost their ability to neutralise Omicron at realistic dosages, they said.

”The bottom line is we have countermeasures to treat Omicron. That’s good news,” said study lead author Yoshihiro Kawaoka, from the University of Wisconsin–Madison in the US.

”However, this is all in laboratory studies. Whether this translates into humans, we don’t know yet,” Kawaoka said.

The findings, published in the New England Journal of Medicine on Wednesday, corroborate other studies that show most available antibody treatments are less effective against Omicron.

The clinically available pills and antibodies were designed and tested before researchers identified the Omicron variant, which differs significantly from earlier versions of the virus.

When Omicron was identified, scientists feared that these differences, caused by mutations in the viral genome, might reduce the effectiveness of drugs designed to treat the original version of the virus.

In lab experiments using non-human primate cells, Kawaoka and colleagues at the National Institute of Infectious Diseases in Japan tested a suite of antibody and antiviral therapies against the original strain of the COVID-19 virus and its prominent variants.

They found that US pharmaceutical company Merck’s pill molnupiravir and the intravenous drug Remdesivir were just as effective against Omicron as they were against earlier viral strains.

Instead of testing Pfizer’s Paxlovid pill, which is designed to be taken orally, the team tested a related drug by the company that is given intravenously.

The two drugs disrupt the same part of the viral machinery.

The researchers found that the intravenous form of the drug retained its effectiveness against Omicron, and this version is currently in clinical trials.

All four antibody treatments the researchers tested were less effective against Omicron than against earlier strains of the virus.

Two treatments, Sotrovimab by GlaxoSmithKline and Evusheld by AstraZeneca, retained some ability to neutralise the virus, according to the researchers.

However, they required anywhere from 3 to 100 times more of the drugs to neutralise Omicron compared to earlier versions, they said.

The study also showed that two antibody treatments by Lilly and Regeneron were unable to neutralise Omicron at common dosages.

The researchers said these findings are expected given how the Omicron variant differs from earlier strains of SARS-CoV-2 virus.

Omicron has dozens of mutations in the spike protein, which the virus uses to enter and infect cells.

Most antibodies were designed to bind to and neutralise the original spike protein and major changes to the protein can make antibodies less likely to attach to it.

In contrast, the antiviral pills target the molecular machinery the virus uses to make copies of itself inside cells, the researchers said.

The Omicron variant only has a few changes to this machinery, which makes it more likely that drugs will retain their ability to disrupt this replication process, they added.

 

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

CM Bommai boasts about Karnataka’s number one position in FDI inflow, as he leaves for Davos

Albanese elected Australia’s leader in complex poll result

Umran Malik selected for T20Is vs SA; Hardik in shortest format, Pujara in Test earn recalls

Bengaluru: Man sentenced to 7 years in jail for abetment to suicide

Shivakumar rejects differences with Siddaramaiah, says together recommended MLC candidates

Taliban enforcing face-cover order for female TV anchors

Amid Gyanvapi controversy, Hindus claim temple in Srirangapatna was converted into Jamia Masjid


Related Articles More

In Your Debt: How debt-related stress affects body and mind

Monkeypox: What is it and how can we prevent the spread?

Treating sleep apnoea can improve memory in people with cognitive decline

Why do we get teary when we’re tired or sick?

Psychedelics: how they act on the brain to relieve depression

MUST WATCH

High tech Bust stand Inaguration at Shirva

NEWS BULLETIN 21-05-2022

We will have 2 options

Chikkamagaluru DC statement Namaz at Dattapeeta video goes viral

Kalasa Crime : CCTV Footage found


Latest Additions

CM Bommai boasts about Karnataka’s number one position in FDI inflow, as he leaves for Davos

Ajay Devgn-like car stunt lands Noida man in jail

Albanese elected Australia’s leader in complex poll result

‘Half Ticket’: Musical comedy paying homage to Kishore Kumar to stage in capital on May 28

Umran Malik selected for T20Is vs SA; Hardik in shortest format, Pujara in Test earn recalls

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.